<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Post-exposure prophylaxis against varicella-zoster virus infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Post-exposure prophylaxis against varicella-zoster virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Post-exposure prophylaxis against varicella-zoster virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary A Albrecht, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myron J Levin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is endemic worldwide. VZV infection causes two clinically distinct diseases: varicella (chickenpox) and herpes zoster (shingles). </p><p class="bulletIndent1"><span class="glyph">●</span>Primary infection with VZV causes chickenpox, with fever and a characteristic vesicular rash. Although varicella is usually a mild, self-limited illness, it can be associated with complications, such as secondary bacterial infection, pneumonia, hepatitis, and encephalitis. Severe, sometimes fatal, complications are more common in adults, certain newborns, immunocompromised people, and pregnant women.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After primary varicella infection, VZV establishes latency in sensory ganglia, and reactivation of latent VZV can result in the painful dermatomal skin infection of herpes zoster. Herpes zoster is most commonly seen in older adults (greater than 50 years of age) and immunocompromised people. Some immunocompromised patients can develop disseminated infection (eg, multiple vesicular skin lesions in a generalized distribution distant from the dermatomes affected by the herpes zoster rash). </p><p></p><p>Patients who are susceptible to VZV infection are at risk of acquiring VZV after a significant exposure to a person with chickenpox or herpes zoster. This topic will provide an overview of the use of active immunization (<a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a>), passive immunization (Varizig), and antiviral post-exposure prophylaxis in nonimmune individuals after a potential exposure to VZV. </p><p>More detailed discussions of post-exposure prophylaxis for pregnant women, transplant recipients, and health care workers, as well as the use of <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> for routine immunization in children and adults, are presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy", section on 'Post-exposure prophylaxis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Varicella exposure'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a>.)</p><p></p><p class="headingAnchor" id="H3937139961"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H879120"><span class="h2">Susceptibility to VZV infection</span><span class="headingEndMark"> — </span>A person is considered susceptible to VZV infection if they do <strong>not</strong> meet one of these criteria for evidence of immunity [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Written documentation of two doses separated by ≥28 days and both doses administered after age 12 months (although an interval ≥3 months between doses is recommended for children ages 1 through 12 years, the second dose is considered valid if the interval is ≥28 days) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">For routine varicella immunization, the first dose is recommended at age ≥12 months and the second at age 4 to 6 years. However, because vaccine failure may occur after a single dose, children &lt;4 years of age are considered susceptible if they have not received two doses separated by ≥28 days. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Breakthrough varicella'</a>.)</p><p></p><p class="bulletIndent1">This criterion is not applicable for patients undergoing allogeneic hematopoietic cell transplant (HCT), which may ablate prior immune responses. Criteria for post-exposure against VZV in HCT recipients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Varicella'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evidence of immunity or laboratory confirmation of disease (eg, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> G [IgG] antibodies to VZV; positive VZV polymerase chain reaction assay, direct fluorescent antibody staining of a specimen, or culture); commercially available antibody assays detect disease-induced antibody but may not reliably detect vaccine-induced antibody. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Post-vaccination serology'</a> and  <a class="medical medical_review" href="/z/d/html/8329.html" rel="external">"Diagnosis of varicella-zoster virus infection"</a>.)</p><p></p><p class="bulletIndent1">Although serologic testing may provide evidence of prior infection in unvaccinated immunocompetent individuals [<a href="#rid3">3</a>], it has a limited role in determining the need for post-exposure prophylaxis because it may be unreliable for detecting immunity in immunocompromised patients and those with immunity due to vaccination. In addition, laboratory turnaround time may not allow for timely preventive interventions (ie, active immunization within five days, passive immunization within 10 days). (See <a class="local">'Approach to post-exposure prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis or verification of prior typical varicella infection or herpes zoster infection by a health care provider. (For people reporting a history of mild or atypical varicella, verification requires documentation of an epidemiologic link to a typical case or to a laboratory-confirmed case because other diseases can mimic mild or atypical varicella [<a href="#rid1">1,4,5</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Birth in the United States before 1980 (when the prevalence of varicella was high) <strong>and not </strong>immunosuppressed, pregnant, or a health care worker. Individuals who are immunosuppressed, pregnant, or health care workers must have serologic evidence of immunity, documentation of completed immunization, or verification of typical disease because they are at increased risk of developing severe infection, increased risk of transmitting varicella to those at high risk for severe infection, and/or increased risk of being exposed to varicella. </p><p></p><p class="bulletIndent1">People born outside the United States before 1980 must satisfy one of the other criteria for evidence of immunity because the prevalence of varicella in the country of origin may not be known. </p><p></p><p class="headingAnchor" id="H628906822"><span class="h2">Significant exposure</span><span class="headingEndMark"> — </span>What constitutes a significant VZV exposure depends upon the type and severity of VZV infection in the source and the type and timing of exposure [<a href="#rid1">1,6</a>]. The risk of acquiring VZV is higher after exposure to persons with varicella than after exposure to persons with localized herpes zoster [<a href="#rid7">7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Source with varicella or disseminated herpes zoster </strong>– VZV is transmitted by inhalation of aerosolized virus from skin lesions and/or infected respiratory secretions [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">"Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Transmission and virology'</a>.)</p><p></p><p class="bulletIndent1">If the source has wild-type varicella (including varicella in a vaccinated individual [ie, breakthrough varicella]) or disseminated herpes zoster infection, we consider household contacts and those who had face-to-face indoor contact for ≥5 minutes to have had a significant exposure to VZV. In a hospital setting, this includes those patients in the same room or in adjacent hospital beds in a large ward. Other experts consider only close-proximity exposures of more than one hour to be significant [<a href="#rid1">1,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Breakthrough varicella'</a>.)</p><p></p><p class="bulletIndent1">Patients with varicella are generally considered infectious from one to two days before the onset of rash until all the lesions have crusted. The secondary attack rate for varicella in susceptible household contacts may be as high as 90 percent [<a href="#rid1">1,9</a>].</p><p></p><p class="bulletIndent1">Patients with disseminated zoster are infectious until all the lesions have crusted. </p><p></p><p class="bulletIndent1">We generally <strong>do not</strong> consider exposure to a source who developed a localized rash after varicella vaccination to be a significant exposure for immunocompetent individuals. Whether it is significant for an immunocompromised host should be considered on a case-by-case basis depending upon the level of immune suppression. Healthy vaccinated persons have a minimal risk for transmitting vaccine-associated virus to contacts, and secondary cases of varicella caused by vaccine virus are generally mild [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Transmission of vaccine virus'</a>.)</p><p></p><p class="bulletIndent1">What constitutes a significant exposure in HCT recipients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Source with localized herpes zoster</strong> – If the source has active localized herpes zoster, we consider the exposure to be significant when a susceptible patient has direct contact (eg, touching, hugging) with the source [<a href="#rid1">1,6</a>]; however, the risk of transmission is considerably lower with localized herpes zoster than with varicella or disseminated zoster infection. </p><p></p><p class="bulletIndent1">In addition, patients may be at risk for VZV transmission if there is close, but not direct, contact with the source because airborne transmission from localized zoster may occur, but it is unclear how frequently this occurs. (See  <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals", section on 'Transmission from persons with zoster'</a>.)</p><p></p><p class="headingAnchor" id="H1987962619"><span class="h1">APPROACH TO POST-EXPOSURE PROPHYLAXIS</span><span class="headingEndMark"> — </span>Management of susceptible patients depends upon the nature of the exposure, the patient's risk of developing serious disease, and whether the patient is eligible for <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H1502926746"><span class="h2">Vaccine prophylaxis for eligible patients</span></p><p class="headingAnchor" id="H2697110127"><span class="h3">Who is eligible?</span><span class="headingEndMark"> — </span>After a significant exposure to VZV, susceptible adults or children should be vaccinated with monovalent <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> if they are eligible; there are no data available on the combination measles, mumps, rubella, varicella vaccine for post-exposure vaccination [<a href="#rid11">11</a>]. To be eligible for vaccine prophylaxis, patients must meet all of the following criteria: </p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not pregnant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not immunocompromised (eg, without primary or acquired T lymphocyte immunodeficiencies; without malignant neoplasms of the bone marrow or lymphatic system; not receiving immunosuppressive therapy); patients with HIV infection are discussed below. (See <a class="local">'Patients with HIV infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No history of severe reaction to <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> or varicella vaccine component.</p><p></p><p>Patients who received antiviral therapy with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a>, or <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> within the previous 24 hours or antibody-containing <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> or blood product within the previous 3 to 11 months  (<a class="graphic graphic_table graphicRef72640" href="/z/d/graphic/72640.html" rel="external">table 1</a>) may have a diminished response to <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a>. For such patients, we individualize decisions about post-exposure vaccination after a discussion of the risks and benefits. </p><p>For children (&lt;18 years of age) who require ongoing salicylate therapy, there is a possible risk of Reye syndrome with varicella vaccination. Although Reye syndrome was associated with the use of salicylates during wild-type varicella infection, no cases of Reye syndrome have been reported following <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> [<a href="#rid1">1</a>]. For children who require salicylate therapy, we individualize decisions about post-exposure vaccination after a discussion of the risks of vaccination versus wild-type infection. </p><p>Post-exposure prophylaxis with <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> prevents infection in 70 to 90 percent of susceptible persons and decreases severity of disease in those who develop varicella [<a href="#rid12">12-18</a>]. Several case series demonstrated that varicella vaccine is efficacious for post-exposure prophylaxis among household contacts of individuals with varicella [<a href="#rid13">13-15</a>]. In one report, 18 susceptible contacts vaccinated within three days of exposure did not develop varicella, whereas 19 unvaccinated contacts developed varicella [<a href="#rid14">14</a>]. </p><p class="bulletIndent1">The efficacy of varicella immunization in containing transmission was also assessed in a retrospective investigation of a varicella outbreak in 1996 (soon after the licensure of <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a>), in which there were exposures comparable to household exposures [<a href="#rid18">18</a>]. Of 214 children enrolled in a day care center, 148 had no prior immunization or history of varicella. Among those who were vaccinated after the exposure, the frequency of varicella was significantly reduced in vaccinated compared with unvaccinated children (14 versus 88 percent). When varicella occurred, the clinical illness was less severe in vaccinated children and resulted in fewer days absent from the day care center. Varicella vaccine was estimated to be 86 percent effective against all forms of disease and 100 percent effective against moderate to severe disease.</p><p></p><p>Although the evidence of benefit in adults is indirect, because most studies were done in children, we administer post-exposure vaccination to adults because of their increased risk of complicated infection.</p><p class="headingAnchor" id="H41178199"><span class="h3">Timing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>≤5 days after exposure</strong> – <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">Varicella vaccine</a> is most effective if it is administered within five days of the exposure. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exposed patients ≥12 months of age who were previously unvaccinated should receive the first dose within five days of the exposure. The recommended timing for the second dose varies with age [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Schedules in the United States'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exposed patients ≥4 years of age who have only received one dose of vaccine should receive the second dose within five days after exposure to varicella provided ≥28 days have elapsed after the first dose. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>&gt;5 days after exposure</strong> – Unvaccinated patients with a significant exposure who present &gt;5 days after exposure can be observed for 21 days to see if disease develops, and treatment can be considered at that time. (See  <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection"</a>.)</p><p></p><p class="bulletIndent1">Alternatively, antiviral prophylaxis may be reasonable, particularly in those who are at increased risk for complications from varicella but who do not meet criteria for varicella <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (eg, adults, adolescents, children with chronic cutaneous or pulmonary disorders, secondary cases in a household). (See <a class="local">'Role of antiviral prophylaxis'</a> below.) </p><p></p><p class="bulletIndent1">If varicella does not develop after 21 days, patients should be vaccinated to prevent future disease. <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">Varicella vaccine</a> should be administered ≥24 hours after discontinuation of antiviral therapy. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a>.)</p><p></p><p class="headingAnchor" id="H859787252"><span class="h3">Eligible patients without significant exposure</span><span class="headingEndMark"> — </span>Susceptible children and adults should be vaccinated against VZV even if it is determined that there was not a significant exposure, since varicella vaccination is recommended for children ≥12 months of age, adolescents, and adults without evidence of immunity [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Indications and schedules'</a>.)</p><p class="headingAnchor" id="H2764863507"><span class="h2">Passive immunoprophylaxis</span><span class="headingEndMark"> — </span>In the post-exposure setting, passive immunoprophylaxis against VZV infection typically consists of <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a>.</p><p class="headingAnchor" id="H1833170250"><span class="h3">Target groups</span><span class="headingEndMark"> — </span>Passive immunization with <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> (eg, Varizig) is indicated for susceptible individuals after a significant exposure if they are ineligible for <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> prophylaxis, at high risk for severe infection and/or complications, <strong>and</strong> can receive immunoprophylaxis within 10 days of exposure [<a href="#rid19">19,20</a>].</p><p>Persons at high risk for severe infection and/or complications who are ineligible for <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> prophylaxis include [<a href="#rid6">6,20</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients of any age who lack evidence of immunity to VZV. This includes those with primary and acquired T lymphocyte immunodeficiencies, persons who are immunocompromised due to an underlying neoplastic disease (eg, hematologic malignancy), and individuals receiving immunosuppressive therapies. However, patients receiving monthly high-dose (≥400 mg/kg) intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) are likely to be protected if the most recent dose of IVIG was administered ≤3 weeks before exposure [<a href="#rid20">20</a>]. Patients with HIV infection are discussed below. (See <a class="local">'Patients with HIV infection'</a> below.)</p><p></p><p class="bulletIndent1">Indications for Varizig in patients undergoing hematopoietic cell transplant (HCT) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women who lack evidence of immunity to VZV. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Newborns of mothers who develop varicella five days before to two days after delivery. Mother-to-child transmission of VZV can occur transplacentally in utero or via close perinatal or postnatal contact. (See  <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">"Varicella-zoster infection in the newborn"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized premature infants born at ≥28 weeks of gestation whose mothers do not have evidence of immunity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized premature infants born at &lt;28 weeks of gestation or who weigh ≤1000 g at birth, regardless of maternal evidence of immunity to varicella.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given their immature T cell immunity, we also consider healthy term infants who are exposed to VZV within the first two weeks of life to be at increased risk for severe varicella <strong>if</strong> the mother does not have evidence of immunity to VZV. Other experts do not consider these infants to be candidates for passive immunoprophylaxis [<a href="#rid6">6</a>].</p><p></p><p>In several small case series, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> products have reduced attack rates after exposure to varicella and modulated the severity of disease (eg, fewer lesions, less visceral involvement) [<a href="#rid21">21-26</a>]. Most studies of immunoprophylaxis have not included a placebo arm, so efficacy is inferred from historical data, which demonstrate transmission rates of greater than 90 percent after household exposure to VZV infection, and which demonstrated high complication rates in immunocompromised children with varicella. Some recipients of zoster immune globulin developed asymptomatic seroconversion, providing evidence of aborted or subclinical infection [<a href="#rid26">26</a>].</p><p>These early studies used products other than Varizig. There are limited clinical data regarding the efficacy of Varizig; however, Varizig is made by a process almost identical to <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> (VZIG). In a study of 60 pregnant females with varicella exposure, patients were randomly assigned to either VZIG or Varizig based on time from exposure (ie, 1 to 4 days or 5 to 10 days) [<a href="#rid22">22</a>]. The efficacy and safety of the two products were similar over the 28-day period of follow-up; 29 percent developed varicella in the Varizig group compared with 42 percent in the VZIG arm. The duration following varicella exposure to the intervention did not affect efficacy.</p><p>There are no published data regarding the efficacy of Varizig in the prevention of varicella infection in HCT recipients or in HIV-infected patients. </p><p class="headingAnchor" id="H1473868118"><span class="h3">Administration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred formulation</strong> – Varizig is the preferred formulation for passive immunization. If Varizig cannot be obtained, then <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> can be used [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Varizig</strong> – Varizig is a purified human <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> made from plasma containing high levels of antivaricella antibodies (IgG) [<a href="#rid27">27</a>]. During preparation, Varizig undergoes filtration and inactivation to decrease the transmission of known viruses, such as HIV and hepatitis viruses. </p><p></p><p class="bulletIndent2">Varizig is administered as a single dose intramuscularly. It is supplied in vials containing 125 international units. It is dosed according to weight as follows: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>&lt;2 kg – 62.5 international units</p><p class="bulletIndent3"><span class="glyph">-</span>2.1 to 10 kg – 125 international units</p><p class="bulletIndent3"><span class="glyph">-</span>10.1 to 20 kg – 250 international units</p><p class="bulletIndent3"><span class="glyph">-</span>20.1 to 30 kg – 375 international units</p><p class="bulletIndent3"><span class="glyph">-</span>30.1 to 40 kg – 500 international units</p><p class="bulletIndent3"><span class="glyph">-</span>≥40 kg – 625 international units</p><p></p><p class="bulletIndent2">Additional information on administration of <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> is discussed in the Lexicomp drug information topic within UpToDate. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> – IVIG contains antivaricella antibody titers that vary from lot to lot. The recommended dose for varicella prophylaxis is 400 mg/kg, administered as a single dose intravenously. IVIG should be considered an alternative therapy, since limited data exist regarding efficacy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time interval from exposure</strong> – Candidates for Varizig should receive it as soon as possible <strong>and</strong> within 10 days of exposure [<a href="#rid20">20</a>]. In an open-label study of post-exposure prophylaxis in 507 immunocompromised individuals, pregnant individuals, and newborn infants, the incidence of varicella was similar whether Varizig was administered ≤96 hours or &gt;96 hours to 10 days after exposure (6.2 and 9.4 percent, respectively) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for additional doses</strong> – In patients who receive immunoprophylaxis, the duration of protection is unknown but is expected to be at least three weeks. If a high-risk patient has another exposure to VZV ≥3 weeks after administration of the initial dose of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (Varizig or IVIG), another dose of Varizig should be administered [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H4248902636"><span class="h3">Monitoring and follow-up</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for varicella</strong> – Patients who have received immunoprophylaxis need close follow-up to determine if immunoprophylaxis was effective, since 20 to 30 percent of patients may still develop infection (although it is usually attenuated) [<a href="#rid21">21</a>]. Patients who receive immunoprophylaxis should be monitored for 28 days after exposure because immunoprophylaxis may prolong the incubation period (typically 10 to 21 days) [<a href="#rid1">1,6,23</a>].</p><p></p><p class="bulletIndent1">Any patient who is at high risk for severe or complicated VZV infection who develops signs and symptoms of varicella should receive prompt antiviral therapy. (See  <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection", section on 'Immunocompromised hosts'</a> and  <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection", section on 'Pregnant women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility for future varicella vaccination</strong> – Patients who receive passive immunization should be evaluated to see if they are eligible to receive <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> at a later date (eg, after delivery for pregnant women, after discontinuation of immunosuppressive therapy). However, varicella vaccine should be delayed at least five months after receipt of Varizig and eight months after receipt of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>  (<a class="graphic graphic_table graphicRef72640" href="/z/d/graphic/72640.html" rel="external">table 1</a>) [<a href="#rid6">6,27</a>].</p><p></p><p class="headingAnchor" id="H1571682878"><span class="h2">Role of antiviral prophylaxis</span><span class="headingEndMark"> — </span>Antiviral prophylaxis with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> or <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> may prevent clinical varicella infection after an exposure, although efficacy data are limited. Antiviral prophylaxis is an option for patients who cannot receive <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> or <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (eg, due to lack of availability, timing, or contraindications). (See <a class="local">'Vaccine prophylaxis for eligible patients'</a> above and <a class="local">'Passive immunoprophylaxis'</a> above.) </p><p class="headingAnchor" id="H282774783"><span class="h3">Potential target groups</span><span class="headingEndMark"> — </span>Decisions regarding antiviral prophylaxis for VZV infection are made on a case-by-case basis, depending in part upon the patient's underlying condition. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients</strong> – Antiviral therapy is not routinely used for post-exposure prophylaxis in immunocompetent patients since vaccination with <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> is the preferred approach, and there are limited data regarding the efficacy of antiviral therapy for preventing disease. In addition, effective treatment can be administered to those who develop disease. (See  <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection"</a>.)</p><p></p><p class="bulletIndent1">However, some clinicians may choose to administer antiviral prophylaxis to susceptible immunocompetent patients who cannot receive the <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> within five days of exposure (eg, due to delay in seeking treatment, limited availability, or contraindication to vaccination). (See <a class="local">'Regimen'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients </strong>– The decision to use <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> prophylaxis in immunocompromised patients must be determined on a case-by-case basis since there are few studies evaluating the efficacy of preventive antiviral therapy in this setting [<a href="#rid29">29,30</a>]. Although antiviral therapy is generally safe, it is unclear how effective it will be since patients with impaired T cell immunity may not develop an immune response to VZV and may still be at risk for infection when antiviral therapy is discontinued, as therapy is virostatic not virucidal. </p><p></p><p class="bulletIndent1">Despite these concerns, some experts routinely administer antiviral therapy to immunocompromised patients if Varizig is not available. (See <a class="local">'Regimen'</a> below.)</p><p></p><p class="bulletIndent1">Prevention of VZV infection in patients undergoing solid organ transplant or HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Varicella exposure'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant women</strong> – The decision to use <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> prophylaxis in pregnant patients who cannot receive immunoprophylaxis must be determined on a case-by-case basis since there are no studies evaluating the efficacy of preventive antiviral therapy in this setting.</p><p></p><p class="headingAnchor" id="H355239560"><span class="h3">Regimen</span><span class="headingEndMark"> — </span>For patients in whom antiviral prophylaxis is chosen, we initiate it on days 7 to 10 after exposure and continue it for one week [<a href="#rid6">6,31-33</a>]. Delaying prophylaxis until days 7 to 10 allows for the early steps of replication to occur and may allow a patient to develop some immunity without developing disease. However, some experts prefer to administer a more prolonged course in highly immunocompromised patients. (See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Varicella exposure'</a>.) </p><p><a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> or <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> is usually used for prophylaxis. Valacyclovir is better absorbed than acyclovir and has a more convenient regimen, but its safety and efficacy have not been established for children &lt;2 years of age. While <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> can be used in adults, we preferentially use valacyclovir for VZV prophylaxis because valacyclovir provides higher antiviral drug concentrations than famciclovir. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children and adolescents</strong>:</p><p></p><p class="bulletIndent1">Doses for patients with normal renal function are as follows [<a href="#rid6">6,34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> – 20 mg/kg per dose (maximum dose 800 mg) four times daily orally for seven days </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">Valacyclovir</a> (for children ≥3 months of age) – 20 mg/kg per dose (maximum dose 1 g) three times daily orally for seven days </p><p></p><p class="bulletIndent1">We check baseline renal function in children if there is concern for dehydration. Dose adjustments for individuals with reduced kidney function are found in the Lexicomp drug information topic within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong>:</p><p></p><p class="bulletIndent1">Doses for patients with normal renal function are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> – 800 mg five times per day orally for seven days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">Valacyclovir</a> – 1 g three times per day orally for seven days</p><p></p><p class="bulletIndent1">Dose adjustments for reduced kidney function are described in the Lexicomp drug information topics within UpToDate.</p><p></p><p>In a nonrandomized study that compared placebo with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> (40 or 80 mg/kg daily in four divided doses) given on days 7 to 9 after exposure and continued for seven days in 50 children with household exposure to varicella, fewer children in the acyclovir group developed varicella (16 versus 100 percent) [<a href="#rid35">35</a>]. Among children in the acyclovir group who developed varicella, the incidence of fever and severity of skin lesions were also reduced. In a subsequent study, a seven-day course of acyclovir prophylaxis started within three days after exposure was largely ineffective compared with initiation 6 to 10 days after exposure [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H3478161030"><span class="h3">Follow-up</span><span class="headingEndMark"> — </span>We typically provide varicella vaccination one to two months after exposure to unvaccinated patients who received antiviral prophylaxis and did not develop varicella, provided they have no contraindications to vaccine. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Contraindications and precautions'</a>.)</p><p>As an alternative, to avoid unnecessary vaccination, it may also be reasonable to obtain varicella serology four to six weeks after exposure and provide immunization to those who are nonimmune.</p><p class="headingAnchor" id="H306439922"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3117462251"><span class="h2">Patients with HIV infection</span></p><p class="headingAnchor" id="H3542694843"><span class="h3">Severely immunocompromised</span><span class="headingEndMark"> — </span>For patients with HIV infection who are severely immunocompromised (eg, children with a CD4 T lymphocyte cell percentage &lt;15 percent and adolescents and adults with CD4 count &lt;200 cells/microL) we favor Varizig for post-exposure prophylaxis if Varizig can be administered within 10 days. This is consistent with guideline recommendations from the United States Department of Health and Human Services [<a href="#rid31">31,36</a>]. Some experts provide antiviral prophylaxis beginning five to seven days after exposure, instead of Varizig, but antiviral prophylaxis has not been formally studied in this population. (See <a class="local">'Administration'</a> above and <a class="local">'Role of antiviral prophylaxis'</a> above.) </p><p><a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">Varicella vaccine</a> is contraindicated in this population. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Contraindications and precautions'</a>.)</p><p class="headingAnchor" id="H624424325"><span class="h3">Not severely compromised</span><span class="headingEndMark"> — </span>Decisions regarding post-exposure prophylaxis in patients with HIV infection who are not severely immunocompromised are made on a case-by-case basis, given the lack of data in this population. For adolescents and adults, we generally prefer antiviral prophylaxis. (See <a class="local">'Role of antiviral prophylaxis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Although <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> is not contraindicated in this population, guideline panels do not recommend varicella vaccine for post-exposure prophylaxis in patients with HIV infection because successful prophylaxis requires a rapid and robust response, which has not been studied in these patient groups [<a href="#rid6">6,31,36</a>]. </p><p></p><p class="headingAnchor" id="H1897166534"><span class="h2">Outbreak setting</span><span class="headingEndMark"> — </span>Varicella vaccination is recommended for control of varicella outbreaks [<a href="#rid1">1,17,18</a>]. During an outbreak, healthy children who had only received one dose of vaccine prior to exposure should receive a second dose, provided that the age-appropriate interval has elapsed since the first dose [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Schedules in the United States'</a>.)</p><p>Persons who are vaccinated for the purpose of post-exposure prophylaxis can return to school immediately.</p><p class="headingAnchor" id="H3930137050"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110219.html" rel="external">"Society guideline links: Varicella-zoster virus"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4003.html" rel="external">"Patient education: Vaccines for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3997.html" rel="external">"Patient education: Chickenpox prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Varicella-zoster virus (VZV) infection causes two clinically distinct diseases: varicella (chickenpox) and herpes zoster (shingles). (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients without evidence of prior varicella infection or vaccination are susceptible to VZV infection after a significant exposure. What constitutes a significant VZV exposure depends upon the type and severity of VZV infection in the source and the type and timing of exposure. The risk of acquiring VZV is higher after exposure to persons with varicella or disseminated herpes zoster than after exposure to persons with localized herpes zoster. (See <a class="local">'Susceptibility to VZV infection'</a> above and <a class="local">'Significant exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of susceptible patients depends upon the nature of the exposure, the patient's risk of developing serious disease, and whether the patient is eligible for post-exposure prophylaxis with <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For susceptible adults or children who are eligible for <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> and had a significant exposure within the last five days, we recommend vaccination with the monovalent varicella vaccine rather than observation or antiviral prophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In observational studies, post-exposure prophylaxis with varicella vaccine prevented infection in ≥70 percent of susceptible persons and decreased severity in those who developed disease. (See <a class="local">'Vaccine prophylaxis for eligible patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For susceptible adults or children who are <strong>ineligible</strong> for <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> prophylaxis and are at greatest risk for severe infection and/or complications, we recommend varicella <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (Varizig) if it can be given within 10 days of exposure (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Passive immunoprophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiviral prophylaxis is an option for patients who cannot receive <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> or <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (eg, due to lack of availability, timing, or contraindications). Decisions regarding antiviral prophylaxis for VZV infection are made on a case-by-case basis, depending in part upon the patient's underlying condition. Although antiviral therapy may reduce the risk of developing varicella infection, there are minimal data on the efficacy of this approach, particularly in immunocompromised patients. (See <a class="local">'Role of antiviral prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Susceptible patients who did not receive <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> after the exposure should be reassessed for future vaccination (eg, pregnant women after delivery, immunocompromised patients no longer receiving immunosuppressive therapy). However, varicella vaccine should be delayed until at least five months after receipt of Varizig or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> and 14 days after <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> therapy. (See <a class="local">'Monitoring and follow-up'</a> above and <a class="local">'Follow-up'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Varicella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on July 09, 2015).</li><li><a class="nounderline abstract_t">Levin MJ, Weinberg A, Schmid DS. Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr 2016; 4.</a></li><li><a class="nounderline abstract_t">Perella D, Fiks AG, Jumaan A, et al. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era. Pediatrics 2009; 123:e820.</a></li><li><a class="nounderline abstract_t">Field N, Amirthalingam G, Waight P, et al. Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England. Vaccine 2014; 32:1213.</a></li><li class="breakAll">American Academy of Pediatrics. Varicella-zoster virus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca IL 2021. p.831.</li><li><a class="nounderline abstract_t">Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728.</a></li><li><a class="nounderline abstract_t">Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990; 116:184.</a></li><li><a class="nounderline abstract_t">Ross AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267:369.</a></li><li><a class="nounderline abstract_t">Marin M, Leung J, Gershon AA. Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review. Pediatrics 2019; 144.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Post-exposure varicalla vaccination. https://www.cdc.gov/vaccines/vpd-vac/varicella/hcp-post-exposure.htm (Accessed on November 02, 2019).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Global Disease Elimination and Eradication as Public Health Strategies. Proceedings of a conference. Atlanta, Georgia, USA. 23-25 February 1998. . MMWR Suppl 1999; 48:1.</a></li><li><a class="nounderline abstract_t">Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998; 17:256.</a></li><li><a class="nounderline abstract_t">Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977; 59:3.</a></li><li><a class="nounderline abstract_t">Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev 2008; :CD001833.</a></li><li><a class="nounderline abstract_t">Masur H, Kaplan JE, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137:435.</a></li><li><a class="nounderline abstract_t">Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115:1488.</a></li><li><a class="nounderline abstract_t">Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278:1495.</a></li><li class="breakAll">VariZIG - Highlights of prescribing information. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM333220.pdf (Accessed on December 22, 2012).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:574.</a></li><li class="breakAll">Levin M, Nelson W, Preblud S, et al. Clinical Trials With Varicella-Zoster Immunoglobulins, Academic Press Inc., Ltd, London 1986. p.255.</li><li><a class="nounderline abstract_t">Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42:267.</a></li><li><a class="nounderline abstract_t">Orenstein WA, Heymann DL, Ellis RJ, et al. Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. J Pediatr 1981; 98:368.</a></li><li><a class="nounderline abstract_t">Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969; 280:1191.</a></li><li><a class="nounderline abstract_t">Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147:737.</a></li><li><a class="nounderline abstract_t">Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974; 290:243.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.</a></li><li><a class="nounderline abstract_t">Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 2019; 14:e0217749.</a></li><li><a class="nounderline abstract_t">Kumar A, Moulik NR, Verma N. Successful prevention of varicella outbreak in an overcrowded paediatric oncology ward using oral acyclovir prophylaxis. J Trop Pediatr 2015; 61:151.</a></li><li><a class="nounderline abstract_t">Ishida Y, Tauchi H, Higaki A, et al. Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir. Pediatrics 1996; 97:150.</a></li><li class="breakAll">AIDS info. Varicella-zoster virus. In: Guidelines for the Prevention and Treatment of Opportunisitic Infections in Adults and Adolescents with HIV (updated September 2019). Available at: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/341/varicella-zoster-virus (Accessed on November 08, 2021).</li><li><a class="nounderline abstract_t">Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69:639.</a></li><li><a class="nounderline abstract_t">Lin TY, Huang YC, Ning HC, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16:1162.</a></li><li><a class="nounderline abstract_t">Kechagia IA, Kalantzi L, Dokoumetzidis A. Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling. Pediatr Infect Dis J 2015; 34:1342.</a></li><li><a class="nounderline abstract_t">Asano Y, Yoshikawa T, Suga S, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92:219.</a></li><li class="breakAll">AIDS info. Varicella-zoster virus. In: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected children (updated December 2019). Available at: https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/419/varicella-zoster-virus (Accessed on November 08, 2021).</li></ol></div><div id="topicVersionRevision">Topic 8273 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27337486" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Herpes Simplex Virus and Varicella-Zoster Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19403475" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871823" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871823" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092852" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathogenesis and current approaches to control of varicella-zoster virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153790" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14494142" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modification of chicken pox in family contacts by administration of gamma globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471448" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471448" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11186140" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Global Disease Elimination and Eradication as Public Health Strategies. Proceedings of a conference. Atlanta, Georgia, USA. 23-25 February 1998. .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9535260" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Postexposure varicella vaccination in siblings of children with active varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/190583" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Protection against varicella in family contacts by immediate inoculation with live varicella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646079" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12617574" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930208" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363968" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363968" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863705" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Updated recommendations for use of VariZIG--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863705" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Updated recommendations for use of VariZIG--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865962" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205447" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4181206" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevention of varicella by zoster immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6341478" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4358055" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Zoster immune globulin. A further assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511443" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25797060" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful prevention of varicella outbreak in an overcrowded paediatric oncology ward using oral acyclovir prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545216" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545216" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285774" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427463" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral acyclovir prophylaxis of varicella after intimate contact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26379165" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393173" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Postexposure prophylaxis of varicella in family contact by oral acyclovir.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
